

## Davidson, Mark

---

**From:** Davidson, Mark  
**Sent:** Friday, April 14, 2017 11:12 AM  
**To:** 'Rizwana Sproule'  
**Cc:** 'Alex Babayan'  
**Subject:** RE: BLA 125643/0 Rolling Submission: Facility / Equipment Request for Information

**Importance:** High

Dear Dr. Sproule,

While conducting our filing review, we identified the following potential review issue:

From the Common Technical Document, you have omitted:

Facility / Equipment information related to manufacture, control, and storage of (b) (4) Vector for the (b) (4) , recommended, per Guidance for Industry Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Vaccine or Related Product, January 1999 and Guidance for Industry: M4Q: The CTD – Quality, January 2001 to be included in the Chemistry, Manufacturing, and Controls (reference section: 3.2.A Appendices – Facilities and Equipment).

The referenced DMF, (b) (4) , does not provide the product specific information, as recommended by the guidance and needed for an effective review. Please provide this information by COB April 18, 2017.

Thank You

Mark L. Davidson, RHIA  
Regulatory Project Manager  
OTAT/CBER/FDA  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Phone: 240-402-8277  
Fax:301-595-1303  
[mark.davidson@fda.hhs.gov](mailto:mark.davidson@fda.hhs.gov)

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."